PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types

PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types

BackgroundImmune checkpoint inhibitors (ICIs) are dramatically changing the treatment landscape of a variety of cancers. Nevertheless, the variability in ICI responses highlight the importance in identifying predictive biomarkers. PTPRD and PTPRT (PTPRD/PTPRT) are the phosphatases of JAK-STAT signal...

Full description

Bibliographic Details
Main Authors: Xiaoling Shang, Wengang Zhang, Xun Zhang, Miao Yu, Jingwen Liu, Yufeng Cheng, Bo Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Immunology
Subjects:
PTPRD
PTPRT
immune checkpoint inhibitors
pan cancer
tumor immune microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.991091/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.991091/full

Similar Items